K

Kymera Therapeutics

Biotech company engineering targeted protein degraders

IT Director - Development Business Partner

Enterprise ApplicationsConfirmed live in the last 24 hours
Full-timeWatertown, MA, USA

About the Job

Requirements

  • 12+ years of IT experience supporting the Development organization in a biotech or pharmaceutical setting.
  • Demonstrated experience taking a company through Phase 3 clinical trials, NDA submission, and commercialization.
  • Hands-on experience with Veeva Vault QMS, eTMF, and CTMS, and a strong command of clinical trial processes, data standards, and GxP requirements.
  • Familiarity with statistical computing environments for clinical submissions, such as SAS-based environments or equivalent, and their validated systems governance.
  • Experience with Regulatory Information Management systems and the requirements of a submission-ready technology landscape.
  • A genuine interest in AI and its practical application, with a drive to identify and execute high-value opportunities.
  • Strong strategic instincts and willingness to work hands-on in a lean, fast-moving environment.
  • Stakeholder management and communication skills to build trust across scientific and operational partners.
  • Comfort managing vendor and implementation partner relationships and holding them accountable to quality, budget, and timeline commitments.
  • Ability to work 3–5 days on-site.

Responsibilities

  • Serve as the primary IT business partner across the Development organization, building trusted relationships with Clinical Operations, Clinical/Medical Development, Quality, Biometrics, Data Management, Regulatory, Program Management, Technical Operations, Medical Affairs, and Pharmacovigilance/Safety.
  • Define and drive the technology roadmap with the Development organization, balancing near-term delivery with long-term positioning for Phase 3 scale and NDA readiness.
  • Identify opportunities to reimagine and streamline Development processes and systems.
  • Partner with the AI lead to identify, prioritize, and execute AI-enabled opportunities within the Development portfolio.
  • Lead technology implementations, including Veeva Vault QMS, eTMF, and CTMS, partnering with business leads, vendors, and implementation partners to deliver validated solutions on time and with high quality.
  • Own the technology strategy and vendor relationships for existing Regulatory, Quality, and Biometrics systems, ensuring they are fit-for-purpose, compliant, and scalable.
  • Partner with the data analytics lead to ensure data integrations and analytic tools support evolving business needs.
  • Scope and evaluate new technology initiatives as Development needs grow, and build and maintain a 2–3-year application roadmap.
  • Lead business requirements gathering, process mapping, and solution design across the Development portfolio in an environment without a dedicated PMO.
  • Translate complex business requirements into validated, fit-for-purpose technology solutions that meet GxP, 21 CFR Part 11, and other applicable regulatory standards.
  • Drive change management, end-user training, and adoption activities to ensure technology investments deliver their intended value.
  • Ensure existing systems and integrations run smoothly.

Desired Qualifications

  • An advanced degree in a life science or technical area.

About the Company

Kymera Therapeutics

Biotech company engineering targeted protein degraders

Kymera Therapeutics develops therapies that remove disease-causing proteins using targeted protein degradation. The company’s Pegasus Platform helps identify which proteins to degrade and then uses molecules that recruit the cell’s waste machinery to break down those proteins, aiming to treat cancers and immune diseases. This approach can create multiple drug candidates across different diseases. Kymera’s products are advanced through collaborations, most notably with Sanofi, which supports research, licensing, and milestone-based payments. Unlike traditional drugs that inhibit a protein’s function, Kymera’s strategy eliminates the protein itself, potentially offering new treatment options for patients. The company’s goal is to deliver new, effective medicines by degrading harmful proteins, expanding options in the biopharmaceutical market and addressing unmet medical needs.

Company size
201-500
Company stage
IPO
Headquarters
Watertown, MA
Founded
2016

Recently Posted Jobs

Explore more opportunities at Kymera Therapeutics

See more jobs